Expert Interview
Digging into Biohaven's BHV-0223 in treating ALS
Ticker(s): BHVN, CTLTA neurologist with experience treating ALS, and knowledge of BHV-0223 and its sublingual delivery method developed in collaboration with Catalent's Zydis ODT fast-dissolve technology.
Please tell us about your clinical experience. How many patients do you currently treat with ALS?
Added By: slingshot_insightsHow do you prevent progression of the disease? What are the pros and cons of using riluzole or edaravone?
Added By: slingshot_insightsHow much of a need is there for a Sublingual Delivery Form for riluzole, that Biohaven is trying to get approved?
Added By: slingshot_insightsWhat percent of your patients have trouble swallowing tablets or liquids? Is it more than 80%, as Biohaven cites?
Added By: slingshot_insightsHow likely would you be to switch your patients to Biohaven’s formulation of riluzole, if approved?
Added By: slingshot_insightsIn its bioequivalence trials, Biohaven showed that sublingual administration of BHV-0223 (40 mg) achieved similar blood exposures to orally ingested Rilutek (50 mg). Is the lower dosage to achieve same results also an advantage here?
Added By: slingshot_insightsAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
